Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
ID: 357330Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357330

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-016.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is offering a funding opportunity titled "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)." This grant aims to support the development and validation of innovative technologies that address significant gaps in heart, lung, blood, and sleep (HLBS) research, focusing on advancing diagnostic and therapeutic solutions with promising preliminary data. Eligible applicants include a wide range of institutions and organizations, with a budget ceiling of $350,000 in direct costs per year, and total funding commitments expected to reach $2,156,000 annually for the next three fiscal years. The application deadline is set for January 11, 2025, and further details can be found on the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-HL-26-016-Full-Announcement.html
    RFA-HL-26-016.html
    The Department of Health and Human Services, through the National Heart, Lung, and Blood Institute (NHLBI), announces the funding opportunity titled “Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research.” This R33 exploratory grant seeks applications aimed at advancing technologies relevant to heart, lung, blood, and sleep (HLBS) disorders. The focus is on further developing and validating technologies that demonstrate promising preliminary data but require further assessment to improve clinical applications and health outcomes. The initiative promotes innovation in predictive, diagnostic, and therapeutic solutions, targeting significant gaps in HLBS research. Applications must outline specific, measurable milestones to monitor progress and include performance measures to evaluate the technology's transformative potential. New applicants and resubmissions are encouraged, with a budget not exceeding $350,000 in direct costs per year, and total funding commitments expected to reach $2,156,000 annually for the next three fiscal years. Eligible applicants include various institutions, nonprofits, and for-profit organizations. The project management protocols require oversight to ensure successful milestone completion. The deadline for applications opens on January 11, 2025, with further details available on the NHLBI website. This opportunity represents a significant government effort to drive advancements in health technologies for HLBS disorders.
    Similar Opportunities
    Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research" grant, aimed at advancing technologies that address heart, lung, blood, and sleep (HLBS) disorders. This funding opportunity specifically seeks R33 exploratory/developmental grant applications that focus on mid-stage developments requiring further validation and refinement, with an emphasis on demonstrating novelty and substantial improvement over existing methods. The initiative is crucial for facilitating transformations in HLBS-related research and clinical practices, promoting the swift adoption of breakthrough technologies. Interested applicants can apply for funding of up to $1.86 million annually, with a submission deadline of December 20, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity (FON: PAR-24-173) aimed at supporting Phase I clinical trials for therapeutics and diagnostics related to heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This initiative utilizes a bi-phasic R61/R33 award mechanism, where the R61 phase focuses on preparatory activities such as finalizing trial protocols and gathering preclinical data, while the R33 phase is dedicated to executing the clinical trial. The funding limits include up to $250,000 annually for the R61 phase and $1,515,000 for the R33 phase, with total support available for a maximum of five years. Interested applicants must adhere to NIH guidelines and submit their proposals by January 7, 2027, to be considered for this opportunity. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is offering a funding opportunity titled "Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products." This initiative aims to support early-stage translational research focused on identifying lead compounds for therapeutic agents targeting heart, lung, blood, and sleep (HLBS) diseases, facilitating their transition into preclinical testing. Eligible applicants include a diverse range of entities such as higher education institutions, nonprofits, and government bodies, with a requirement for a non-federal cash match of at least 25% of the federal direct costs. The total anticipated funding over three years is approximately $13.4 million, with project budgets capped at $400,000 per year and a maximum project period of two years. Applications must be submitted by December 23, 2027, and further inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity titled "Catalyze Product Definition," aimed at supporting the development of medical device prototypes, diagnostic targets, and related research tools for heart, lung, blood, and sleep (HLBS) diseases. This initiative adopts a phased approach (R61/R33) to assist early-stage projects, focusing on preliminary prototype testing in the R61 phase and advancing to extensive development activities in the R33 phase, with a requirement for applicants to demonstrate novelty and a strong biological rationale supported by preliminary data. The program anticipates funding approximately $4.4 million annually from FY 2026 to FY 2028, with up to 24 awards available, and requires applicants to engage with an Accelerator Partner to enhance commercialization expertise. Interested parties can find more information and application guidelines at the NIH grants website, with a submission deadline of December 23, 2027.
    Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation" (RFA-HL-23-014). This grant aims to support early-stage translational research focused on developing devices, diagnostics, and research tools for heart, lung, blood, and sleep (HLBS) diseases, with an emphasis on prototype testing, user feedback, and regulatory strategies. The total funding available is up to $6.3 million per year, and applicants are required to provide substantial evidence of unmet medical needs and preliminary data, along with a minimum cash match of 25% from non-federal sources. Applications are due by December 20, 2024, and further inquiries can be directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov. More details can be found at the provided link: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-014.html.
    Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)" aimed at supporting early-stage translational research for developing therapeutic agents targeting heart, lung, blood, and sleep disorders. This initiative seeks to identify lead compound series and bridge the gap between basic science discoveries and preclinical testing, emphasizing innovation through novel therapeutic approaches and strong biological rationale. The grant offers a maximum funding amount of $350,000 over a two-year period, with no cost-sharing requirement, and applications are due by December 20, 2024. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-012.html.
    Catalyze: Product Definition Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalyze: Product Definition Device Prototype Design and Testing," aimed at providing early-stage translational support for the development of devices, diagnostic targets, and research tools addressing heart, lung, blood, and sleep (HLBS) disorders. This initiative includes two phases: the R61 phase focuses on initial prototype design and testing, while the R33 phase emphasizes further development and validation, requiring a non-Federal cash match for the latter. The program is critical for advancing innovative solutions in public health, with anticipated awards totaling up to $6,277,500 annually for up to 13 projects per year. Interested applicants must submit their proposals by December 20, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Catalyze: Product Definition – Medical Device Prototype Optimization" (RFA-HL-26-020) aimed at supporting early-stage translational research for the optimization of prototypes related to heart, lung, blood, and sleep (HLBS) diseases. This initiative seeks to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates, encouraging significant improvements over existing solutions through strong biological rationale and preliminary data. The total anticipated funding is approximately $4.466 million per fiscal year from FY 2026 to FY 2028, with applications due by 5 PM local time on specified dates, and a maximum project duration of two years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products," aimed at supporting early-stage translational research for heart, lung, blood, and sleep disorders. This initiative employs a phased approach (R61/R33), where the R61 phase focuses on identifying and validating therapeutic candidates, while the R33 phase involves lead series identification for preclinical testing, emphasizing innovation and addressing therapeutic gaps. The total funding commitment is approximately $4.47 million per fiscal year from 2026 to 2028, with a maximum budget of $400,000 per year for each phase, and applications are due by December 23, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.